Claims What is claimed is:
. 1. Acondensedpyrimidine derivative represented by formula (I) or
pharmaceutical^ acceptable salt thereof; [Formula 10]

wherein
A represents a ring selected from the group consisting of Group X , Group X , Group X3, and Group X4, (a) carbon atom(s) composing said ring being optionally substituted^ with one or more groups selected from the group consisting of lower alkyl, -0~(iower alkyl), halogen atom, carboxyl, -CC>2-(low^r alkyl), and carbamoyl, the sulfur atom composing Said ring being optionally oxidized, Group X1 consisting of: [Formula 11]

Group X3 consisting of:

LFoimula 13]
LJ

Group X4 consisting of; [Formula 14]

R1 represents a group selected from Groups (1) to (3),
(1) phenyl substituted with at least one halogen atom, which may have (an) additional substituent(s),
(2) cyclopropyl, cyclobutyl, cyclop entyl7 cyclohexyl, or cycloheptyl, each of which is optionally substituted, and
(3) pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, thienyl, thiazolyl, oxazolyl,
imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, or furyl substituted with at least one
halogen atom, each of which is optionally substituted with one or. more identical or
different halogen atoms, wherein the ring bonds to the 2-position of the pyrimidine ring
in formula (1) at a carbon atom composing said ring,
proyided that when A is a ring selected from Group X4, R1 represents phenyl substituted with at least three halogen atoms; and
R represents a group represented by foimula (II) or optionally substituted cyclic amino: [Foimula 15]

wherein R» and Rn may be identical or different and each represents -H, lower alkyl,

lower alkenyl, lower alkynyl, cycloalkyl, phenyl, heteroaryl, non-aromatic heterocyclyl,
or -0-(l6wer alkyl), each of which is optionally substituted,
provided that when A is a ring selected from Group X2 or Group X3, R2 represents
optionally substituted cyclic amino,
provided that
2-(2'-fluorophenyl)-N,N-dimethyl-5^
2-cyclopropyl-4-piperarin«l-yl-5 J-dihydrothieno[3?4-d]pyrimidine are excluded:
2. The compound according to Claim 1, wherein A is a ring selected from Group X5-
3. The compound according to Claim 2, wherein R1 is phenyl substituted with at least one halogen atom*
4. The compound according to Claim 3, wherein R1 is phenyl substituted with at least three halogen atoms.
5. The compound according to Claim 4, wherein R2 is optionally substituted cyclic amino.
6. The compound according to Claim 5, wherein R2 is optionally substituted piperazinyl or optionally substituted piperidinyl.
7. The compound according to Claim 2, wherein R1 is cyclopropyl, cyclobutyl, cyclopentylj cyclohexyl, or cycloheptyl, each of which is optionally substituted.
8. The compound according to Claim 7, wherein R1 is cyclobutyl or cyclopentyl, each of which is optionally substituted.
9. The compound according to Claim 8, wherein R2 is optionally substituted cyclic amino.
10. The compound' according to Claim 9, wherein R2 is optionally substituted piperazinyl or optionally substituted piperidinyl.
11. The compound according to Claim 1 „ selected from the group consisting of 3-{4-[2^4-cUoro-2»5-difluoropheny

-yljpiperazin-1 -yl}propanamide3 . l-[2-(4-cMoro-2,5-ditfluorophenyl>^^ -4-(3-hydroxypropyl)piperidin-4-ol, N<{l-[2-{4-cMoro-2?5Klifluorophenyi-6,6^^^ 4-yl)piperidin^yl]melhyl}-2-hydroxyacetainide> 3-{ 1 -[2^4-chloro-295-dmuorop^ -yljpiperidin-4~yl}propanamide? 3<{l-[2-(4-chloro-2,5-difluorophenyl>6,6^o 4-ylJpiperidin-4-yl} amino)propan-1 -oL,
3^{l-[2-(4-cMoro-2?5-difluorophenyl)-6,6-dioxido-5J-dihydrothieno[3s4-d]p 4-yl]pijperidin"4-yl}amino)propionicacid, 4-[l-(2-cyclopentyl-6,6-dioxid^ butyric acid,
4~[ 1 -(2-cyclobu1yl^36^ioxido-5,7-dihydrotteeno[3,4-d]pyriiuidin-4-yl)piperidifi-4-yl]b utyric acid,
4-{l-[2-(4-cMoro-2,5niifluorophenyl)^676"dio^ -yl]piperidin-4-yl}butyric acid, and pharmaceutically acceptable salts thereof.
12. A pharmaceutical composition comprising the compound according to Claim 1'
35 an active ingredient
13. The pharmaceutical composition according to Claim 12, as a therapeutic agent for.insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant disease, or obesity.
14. The pharmaceutical composition according to Claim 12, as an insulin, secretagogue.
15. The pharmaceutical composition according to Claim 12, as a hyperglycemic
inhibitor.
Dated this 19 day of April 2007